Literature DB >> 28624138

Serum NCAM levels and cognitive deficits in first episode schizophrenia patients versus health controls.

HuiMei An1, LuPing Zhou2, Yinghua Yu3, Hongzhen Fan1, FengMei Fan1, Shuping Tan1, ZhiRen Wang1, Boz Z3, Jing Shi1, FuDe Yang1, Xiangyang Zhang1, Yunlong Tan1, Xu-Feng Huang4.   

Abstract

BACKGROUND: Neural cell adhesion molecule (NCAM) is a glycoprotein and plays an important role in cell-cell adhesion, neural migration, neurite outgrowth, synaptic plasticity and brain development. We investigated the relationship between the serum NCAM concentration and cognitive deficit in first episode drug naïve schizophrenia (FES) patients.
METHODS: Thirty FES patients and thirty healthy controls were recruited for this study. Psychiatric symptoms were assessed by the positive and negative syndrome scale (PANSS). Cognitive functions were assessed by measurement and treatment research to improve cognition in schizophrenia (MATRICS) and consensus cognitive battery (MCCB). Serum levels of NCAM were determined by ELISA.
RESULTS: Schizophrenia patients had decreased serum NCAM concentrations than controls (-30%, p<0.001). Cognitive scores were significantly lower in FES patients than healthy controls (-34%, p<0.001). The NCAM concentrations were positively correlated with the total scores of MCCB (r=0.438, p=0.003). Multiple regression analysis confirmed that serum NCAM concentration was an independent contributor to MCCB total Scores.
CONCLUSIONS: There were a close relationship between the serum NCAM concentrations and cognitive deficits in FES patients. Since NCAM has an important role in neurodevelopmental processes, these results support the neurodevelopmental dysfunction hypothesis of schizophrenia and suggest that an altered NCAM may be one of the risk factors for schizophrenia including cognitive deficits.
Copyright © 2017 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Cognitive deficits; Neural cell adhesion molecule; Schizophrenia; Synaptic plasticity

Mesh:

Substances:

Year:  2017        PMID: 28624138     DOI: 10.1016/j.schres.2017.06.011

Source DB:  PubMed          Journal:  Schizophr Res        ISSN: 0920-9964            Impact factor:   4.939


  7 in total

1.  Relationship Between Neural Cell Adhesion Molecule-1 and Cognitive Functioning in Schizophrenia Spectrum Disorder.

Authors:  Neha Keshri; Hanumanthappa Nandeesha; Medha Rajappa; Vikas Menon
Journal:  Indian J Clin Biochem       Date:  2021-01-03

2.  Plasma Biomarkers as Potential Predictors of Functional Dependence in Daily Life Activities after Ischemic Stroke: A Single Center Study.

Authors:  Adina Huțanu; Mihaela Iancu; Smaranda Maier; Rodica Bălaşa; Minodora Dobreanu
Journal:  Ann Indian Acad Neurol       Date:  2019-05-14       Impact factor: 1.383

Review 3.  NCAM Mimetic Peptides: Potential Therapeutic Target for Neurological Disorders.

Authors:  Chengyan Chu; Yue Gao; Xiaoyan Lan; Aline Thomas; Shen Li
Journal:  Neurochem Res       Date:  2018-07-12       Impact factor: 3.996

4.  Meta-analysis of cognitive function in Chinese first-episode schizophrenia: MATRICS Consensus Cognitive Battery (MCCB) profile of impairment.

Authors:  Huijuan Zhang; Yao Wang; Yuliang Hu; Yikang Zhu; Tianhong Zhang; Jijun Wang; Ke Ma; Chuan Shi; Xin Yu; Chunbo Li
Journal:  Gen Psychiatr       Date:  2019-07-22

5.  Suicide Related Phenotypes in a Bipolar Sample: Genetic Underpinnings.

Authors:  Line K M Lybech; Marco Calabró; Silvana Briuglia; Antonio Drago; Concetta Crisafulli
Journal:  Genes (Basel)       Date:  2021-09-23       Impact factor: 4.096

6.  Autoantibodies against NCAM1 from patients with schizophrenia cause schizophrenia-related behavior and changes in synapses in mice.

Authors:  Hiroki Shiwaku; Shingo Katayama; Kanoh Kondo; Yuri Nakano; Hikari Tanaka; Yuki Yoshioka; Kyota Fujita; Haruna Tamaki; Hironao Takebayashi; Omi Terasaki; Yukihiro Nagase; Teruyoshi Nagase; Tetsuo Kubota; Kinya Ishikawa; Hitoshi Okazawa; Hidehiko Takahashi
Journal:  Cell Rep Med       Date:  2022-04-19

Review 7.  Electrochemical sensing of blood proteins for mild traumatic brain injury (mTBI) diagnostics and prognostics: towards a point-of-care application.

Authors:  Nadezda Pankratova; Milica Jović; Marc E Pfeifer
Journal:  RSC Adv       Date:  2021-05-12       Impact factor: 4.036

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.